Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia

PURPOSE: In X-linked hypophosphatemia (XLH), excess fibroblast growth factor-23 causes hypophosphatemia and low calcitriol, leading to musculoskeletal disease with clinical consequences. XLH treatment options include conventional oral phosphate with active vitamin D, or monotherapy with burosumab, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Linglart, Agnès, Imel, Erik A, Whyte, Michael P, Portale, Anthony A, Högler, Wolfgang, Boot, Annemieke M, Padidela, Raja, van’t Hoff, William, Gottesman, Gary S, Chen, Angel, Skrinar, Alison, Scott Roberts, Mary, Carpenter, Thomas O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851952/
https://www.ncbi.nlm.nih.gov/pubmed/34636899
http://dx.doi.org/10.1210/clinem/dgab729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851952/
https://www.ncbi.nlm.nih.gov/pubmed/34636899
http://dx.doi.org/10.1210/clinem/dgab729

Ejemplares similares